Goodwin Procter partner Charles A. Brown has entered an appearance for Fulcrum Therapeutics Inc., its former and current CEO and CFO in a pending securities class action. The complaint, which centers on FTX-6058, a drug candidate developed by Fulcrum to treat sickle cell disease and other hemoglobin molecule disorders, was filed April 28 in New Jersey District Court by Pomerantz LLP. The action alleges that the defendants failed to inform shareholders about safety concerns surfaced in preclinical data for the drug and about the likelihood that the Food and Drug Administration would place a hold on further drug studies. The case, assigned to U.S. District Judge Renee Marie Bumb, is 1:23-cv-02360, Celano v. Fulcrum Therapeutics, Inc. et al.

This suit was surfaced by Law.com Radar, a source for high-speed legal news and litigation updates personalized to your practice. Law.com Radar publishes daily updates on just-filed federal cases like this one. Click here to get started and be first to know about new suits in your region, practice area or client sector.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]